CEO, PRESIDENT, GLAUKOS
WHY: Ophthalmic company focused on devices and drugs to treat glaucoma, corneal disorders and retinal diseases. Pioneered the micro-invasive glaucoma surgery (MIGS) marketplace. Its best-known product is the iStent, which is among the smallest medical devices ever made.
IN THE NEWS: Revealed positive Phase 3 results for new eye treatment called iDoseTR, sending shares up 21% in early September. Full FDA approval predicted by end of 2023.
NOTABLE: Made long-awaited HQ move from San Clemente to Aliso Viejo in 2022.
